Đang chuẩn bị liên kết để tải về tài liệu:
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall survival (OS). | A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus HF10 for unresectable locally advanced pancreatic cancer

TÀI LIỆU LIÊN QUAN

Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC

Optimal biological dose: A systematic review in cancer phase I clinical trials

Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials

Clinical Phase I/II trial to Investigate Preoperative Dose-Escalated Intensity-Modulated Radiation Therapy (IMRT) and Intraoperative Radiation Therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: Interim analysis

A phase I/II clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced cervical cancer

Single fraction ablative preoperative radiation treatment for early-stage breast cancer: The CRYSTAL study – a phase I/II clinical trial protocol

Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: A prospective phase I subanalysis

A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma

A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome

Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): Study protocol of a phase I/II clinical trial
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.